Tag Archives: John Newman
Regeneron (REGN) Gets a Hold Rating from Canaccord Genuity
In a report released today, John Newman from Canaccord Genuity maintained a Hold rating on Regeneron (REGN – Research Report), with a price target of $320.00. The company’s shares closed last Monday at $285.10, close to its 52-week low of
Analysts Are Bullish on These Healthcare Stocks: Agios Pharma (AGIO), Tactile Systems Technology (TCMD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agios Pharma (NASDAQ:AGIO) and Tactile Systems Technology (NASDAQ:TCMD) with bullish sentiments. Agios Pharma (AGIO) In a report released today, John Newman from
Gemphire Therapeutics (GEMP) Gets a Buy Rating from Canaccord Genuity
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Gemphire Therapeutics (NASDAQ: GEMP), with a price target of $6. The company’s shares opened today at $1.61, close to its 52-week low of $0.83. Newman
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (NASDAQ: ALDX) and Regulus (NASDAQ: RGLS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aldeyra Therapeutics (NASDAQ:ALDX) and Regulus (NASDAQ:RGLS). Aldeyra Therapeutics (ALDX) In a report released today, John Newman from Canaccord Genuity maintained a Buy rating
Analysts’ Top Healthcare Picks: Agios Pharma (AGIO), Intra-Cellular Therapies (ITCI)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agios Pharma (NASDAQ:AGIO), Intra-Cellular Therapies (NASDAQ:ITCI) and Adaptimmune Therapeutics (NASDAQ:ADAP) with bullish sentiments. Agios Pharma (AGIO) In a report released today, John
Analysts Offer Insights on Healthcare Companies: Aduro BioTech (NASDAQ: ADRO) and Dexcom (NASDAQ: DXCM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aduro BioTech (NASDAQ:ADRO) and Dexcom (NASDAQ:DXCM) with bullish sentiments. Aduro BioTech (ADRO) Canaccord Genuity analyst John Newman maintained a Buy rating on
